Morgan Stanley’s Matinas BioPharma MTNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $211 | Hold |
344
| – | – | ﹤0.01% | 7840 |
|
|
2026
Q1 | $172 | Sell |
344
-217
| -39% | -$136 | ﹤0.01% | 7708 |
|
|
2025
Q4 | $328 | Hold |
561
| – | – | ﹤0.01% | 7573 |
|
|
2025
Q3 | $1.06K | Buy |
561
+417
| +290% | +$599 | ﹤0.01% | 7386 |
|
|
2025
Q2 | $128 | Hold |
144
| – | – | ﹤0.01% | 7620 |
|
|
2025
Q1 | $75 | Hold |
144
| – | – | ﹤0.01% | 7622 |
|
|
2024
Q4 | $73 | Sell |
144
-376
| -72% | -$572 | ﹤0.01% | 7518 |
|
|
2024
Q3 | $1.84K | Sell |
520
-400
| -43% | -$2.55K | ﹤0.01% | 7145 |
|
|
2024
Q2 | $7.28K | Sell |
920
-30
| -3% | -$272 | ﹤0.01% | 6762 |
|
|
2024
Q1 | $12.9K | Buy |
950
+400
| +73% | +$4.75K | ﹤0.01% | 6607 |
|
|
2023
Q4 | $5.95K | Sell |
550
-50
| -8% | -$564 | ﹤0.01% | 6793 |
|
|
2023
Q3 | $3.9K | Hold |
600
| – | – | ﹤0.01% | 6972 |
|
|
2023
Q2 | $10.8K | Sell |
600
-145
| -19% | -$3.38K | ﹤0.01% | 6790 |
|
|
2023
Q1 | $17.5K | Sell |
745
-34
| -4% | -$859 | ﹤0.01% | 6674 |
|
|
2022
Q4 | $19.5K | Buy |
779
+381
| +96% | +$12.7K | ﹤0.01% | 6704 |
|
|
2022
Q3 | $13K | Sell |
398
-399
| -50% | -$15.7K | ﹤0.01% | 6984 |
|
|
2022
Q2 | $31K | Sell |
797
-262
| -25% | -$9.99K | ﹤0.01% | 6822 |
|
|
2022
Q1 | $43K | Sell |
1,059
-371
| -26% | -$13.7K | ﹤0.01% | 6780 |
|
|
2021
Q4 | $72K | Buy |
1,430
+341
| +31% | +$18.2K | ﹤0.01% | 6624 |
|
|
2021
Q3 | $71K | Buy |
1,089
+43
| +4% | +$1.85K | ﹤0.01% | 6552 |
|
|
2021
Q2 | $41K | Buy |
1,046
+257
| +33% | +$11K | ﹤0.01% | 6748 |
|
|
2021
Q1 | $42K | Buy |
789
+5
| +0.6% | +$335 | ﹤0.01% | 6429 |
|
|
2020
Q4 | $54K | Buy |
784
+184
| +31% | +$8.52K | ﹤0.01% | 6141 |
|
|
2020
Q3 | $23K | Buy |
600
+443
| +282% | +$17.6K | ﹤0.01% | 6008 |
|
|
2020
Q2 | $6K | Sell |
157
-14,137
| -99% | -$542K | ﹤0.01% | 6276 |
|
|
2020
Q1 | $429K | Buy |
14,294
+13,948
| +4,031% | +$842K | ﹤0.01% | 4464 |
|
|
2019
Q4 | $39K | Buy |
+346
| New | +$20K | ﹤0.01% | 5929 |
|
|
2019
Q3 | – | Sell |
-20
| Closed | -$1K | – | 6705 |
|
|
2019
Q2 | $1K | Hold |
20
| – | – | ﹤0.01% | 6554 |
|
|
2019
Q1 | $1K | Sell |
20
-20
| -50% | -$1.08K | ﹤0.01% | 6523 |
|
|
2018
Q4 | $2K | Hold |
40
| – | – | ﹤0.01% | 6420 |
|
|
2018
Q3 | $2K | Sell |
40
-6,377
| -99% | -$137K | ﹤0.01% | 6579 |
|
|
2018
Q2 | $139K | Buy |
6,417
+3,374
| +111% | +$97.5K | ﹤0.01% | 5659 |
|
|
2018
Q1 | $116K | Buy |
3,043
+387
| +15% | +$20.5K | ﹤0.01% | 5661 |
|
|
2017
Q4 | $154K | Buy |
2,656
+480
| +22% | +$30.9K | ﹤0.01% | 5502 |
|
|
2017
Q3 | $143K | Buy |
2,176
+1,177
| +118% | +$78.6K | ﹤0.01% | 5474 |
|
|
2017
Q2 | $85K | Sell |
999
-1,167
| -54% | -$157K | ﹤0.01% | 5694 |
|
|
2017
Q1 | $300K | Buy |
+2,166
| New | +$353K | ﹤0.01% | 5116 |
|
Other funds holding MTNB
HIW
SIG
Morgan Stanley's MTNB Position: Q2 2026 in Review
Morgan Stanley held its Matinas BioPharma (MTNB) position steady in Q2 2026 at 344 shares worth $211. The position accounts for ﹤0.01% of the portfolio, ranked #7840.
Morgan Stanley first reported a position in MTNB in Q1 2017 and has held it in 37 quarters since. The position peaked at $429K in Q1 2020. 25 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.
- Morgan Stanley held 344 shares of Matinas BioPharma worth $211 as of Q2 2026.
- Morgan Stanley left its Matinas BioPharma share count unchanged in Q2 2026.
- Matinas BioPharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7840 holding.
- Morgan Stanley first reported a position in Matinas BioPharma in Q1 2017 and has held it in 37 quarters since.
- Morgan Stanley's Matinas BioPharma position peaked at $429K in Q1 2020.
- 25 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.